Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B.
- Author:
Lijuan ZHANG
1
;
Yijie CHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenine; administration & dosage; analogs & derivatives; Administration, Oral; Adult; Aged; Antiviral Agents; administration & dosage; Biomarkers; analysis; Drug Therapy, Combination; Drugs, Chinese Herbal; administration & dosage; Female; Hepatitis B, Chronic; complications; drug therapy; Humans; Liver; metabolism; Liver Cirrhosis; prevention & control; virology; Male; Middle Aged; Organophosphonates; administration & dosage; Young Adult
- From: China Journal of Chinese Materia Medica 2012;37(6):862-864
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil.
METHODNinty and four cases of chronic viral hepatitis B patients were randomly divided into two groups. The treatment group (50 cases) was orally given 10 mg of adefovir dipivoxil once a day, 1 Wan each time, combined with Dahuang Zhechong Wan, 3 times a day, 1 Wan each time. And the control group (44 cases) was treated with adefovir dipivoxil alone, 6 months as a course.
RESULTBoth the difference of liver fibrosis indexes between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P < 0.01 or P < 0.05). Both the difference of experimental markers such as ALT, AST, GGT, TBIL between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P < 0.01).
CONCLUSIONDahuang Zhechong Wan combined with adefovir dipivoxil could prevent hepatic fibrosis in patients with chronic hepatitis B, reduce the incidence of liver cirrhosis, improve life quality and prognosis.
